Changes are happening - please bear with us while we update our site.

Changes are happening - please bear with us while we update our site. Click here to give us your advice and feedback.

The S&P/ASX 200 (XJO) just partied like it’s 2019

The S&P/ASX 200 (ASX: XJO) finished the day trading at 5539.3, or 4.42% higher, having fallen more than 6% down this morning. That makes today a 10% snap-back for the ASX 200!

The S&P/ASX 200 (ASX: XJO) finished the day trading at 5539.3, or 4.42% higher, having fallen more than 6% down this morning. That makes today a 10% snap-back for the ASX 200!

Party like it’s 2019!

Making today’s ASX sharemarket headlines were the following companies

  • Cochlear Limited (ASX: COH) – up 21%
  • CSL Limited (ASX: CSL) – up 12%
  • Fortescue Metals Group Limited (ASX: FMG) – up 13%
  • Netwealth Ltd (ASX: NWL) – up 18%
  • Oil Search Ltd (ASX: OSH) – up 17%

Featured interview: Matt Joass, Maven Funds

If you’re looking for interviews with some of Australia’s most sophisticated investors, start with the free video from The Australian Investors Podcast, above. It features Maven Funds Management founder and chief investment officer, Matt Joass, CFA.

ASX 200 Recap

Health stocks shoot upwards

Two of Australia’s most highly regarded medical technology companies, Cochlear and CSL, led the ASX 200 upwards today. Despite their sudden rise however, neither company released material news to the market.

As we know, Cochlear is one of the world’s leading medical businesses. It designs, manufactures and supplies the Nucleus cochlear implant, the Hybrid electro-acoustic implant and the Baha bone conduction implant. Graeme Clark invented the first device in 1982, allowing first-user Graham Carrick to hear for the first time for 17 years. Some of the most recent modifications allow users to play sound from their phone directly into their implant.

CSL is Australia’s largest (and some might say best) healthcare company, specialising in biopharmaceuticals. Founded in the late 1900s as the Commonwealth Serum Laboratories, CSL was sold by the Australian Government to Australian investors via the share market in 1994 at $2.30 per share.

While some people might be speculating that CSL could help the planet solve the Coronavirus outbreak it’s important to note that COVID-19 is quite different to the influenza virus for which CSL is known to be one of the world’s leading treatment providers.

“However, we have investigated possible adjacencies in expertise, technologies and facilities that might be able to contribute to the global effort and are pleased to advise that we have partnered with the University of Queensland’s COVID-19 vaccine development program,” CSL said in a media release in February.

We will provide technical expertise as well as a donation of Seqirus’ proprietary adjuvant technology, MF59®, to their pre-clinical development program.”

Worst ASX 200 performers

At the other side of the performance spectrum today, the worst performers on the ASX included Qantas Airways Ltd (ASX: QAN), Sydney Airport Holdings Ltd (ASX: SYD) and Unibail Rodamco (ASX: URW). Qantas was the worst performer in the ASX 200, falling 12.6%.

This morning, Virgin Australia Ltd (ASX: VAH) provided an update to investors about its planned reductions in flying for the remainder of the financial year. Virgin shares started the day down 10% — yet ended up 32%! You can read more about Virgin’s update by clicking here.

Finally, while this turnaround didn’t end in green numbers and arrows, sports betting company PointsBet Holdings Ltd (ASX: PBH) traded down 25% at one point yet ended just 7% lower — meaning, it staged an 18% recovery.

Days like today — with intense volatility — are reminiscent of the days during the Global Financial Crisis (GFC) where blue-chip shares bounced up or down 20% (or more) in a single day.

Could the opportunity in front of investors really be turning around?

I reckon it’s safe to assume we’ve still got a few bumpy days ahead of us.

[ls_content_block id=”14947″ para=”paragraphs”]

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report for FREE by CLICKING HERE NOW and creating a 100% FREE Rask Account.

(Psst. By creating a free Rask account, you’ll also get access to 15+ online courses, 1,000+ podcasts, invites to events, a weekly value investing newsletter and more!)

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

Skip to content